Article

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment

2022-12-21

Abstract excerpt

Although RAS mutations occur in about 30% of solid tumors, targeting RAS mutations other than KRAS-G12C is still challenging. As an alternative approach, developing inhibitors targeting RAF, the downstream effector of RAS signaling, is currently one of the main strategies for cancer therapy. Selective BRAF-V600E inhibitors Vemurafenib, Encorafenib, and Dabrafenib have been approved by FDA and received remarkable c...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3f51a71f-9a9f-5058-82a6-af868a8d0646
DOI: 10.21203/rs.3.rs-2376757/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatmentDOI 10.21203/rs.3.rs-2376757/v1Read

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.Semantic proximity Read

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.Semantic proximity Read

The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition.Semantic proximity Read

Small-molecule RAS/RAF Binding Inhibitors Allosterically Disrupt RAF Conformation and Exert Efficacy Against a Broad Spectrum of RAS-driven CancersSemantic proximity Read

Drug resistance in targeted cancer therapies with RAF inhibitorsSemantic proximity Read

Raf: a strategic target for therapeutic development against cancer.Semantic proximity Read

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trialsSemantic proximity Read

Novel RAF-directed approaches to overcome current clinical limits and block the RAS/RAF node.Semantic proximity Read

Recent advances in B-RAF inhibitors as anticancer agents.Semantic proximity Read

Mutant B-Raf Kinase Inhibitors as Anticancer Agents.Semantic proximity Read

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.Semantic proximity Read

A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation.Semantic proximity Read